Lequn Q. Li
Nanning, 530021, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Transcatheter Arterial Chemoembolization May Be Selectively Indicated as Postoperative Adjuvant Therapy for Hepatocellular Carcinoma Patients with Microvascular Invasion.
Journal: Journal of hepatocellular carcinoma
Published: August 14, 2025
Lnc-EST885 promotes hepatocellular carcinoma metastasis through PI3K / AKT pathway by interaction with TRAF4.
Journal: Translational oncology
Published: November 07, 2024
The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD‑1 Inhibitors.
Journal: Journal of hepatocellular carcinoma
Published: June 07, 2024
Value of hepatic artery digital subtraction angiography in the detection of small hepatocellular carcinoma lesions.
Journal: Environmental toxicology
Published: February 24, 2024
Single cell-spatial transcriptomics and bulk multi-omics analysis of heterogeneity and ecosystems in hepatocellular carcinoma.
Journal: NPJ precision oncology
Published: January 27, 2024
TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
Journal: BMC cancer
Published: December 10, 2023
Radiotherapy is superior to transarterial chemoembolization as adjuvant therapy after narrow-margin hepatectomy in patients with hepatocellular carcinoma: A single-center prospective randomized study.
Journal: Langenbeck's archives of surgery
Published: October 12, 2023
Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: May 06, 2023
D-dimer to lymphocyte ratio can serve as a potential predictive and prognostic value in colorectal cancer patients with liver metastases.
Journal: BMC surgery
Published: December 26, 2022
Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors.
Journal: Frontiers in oncology
Published: November 29, 2022
Serum immune biomarker levels combined with hepatitis B virus infection status predict early recurrence of early-stage hepatocellular carcinoma with microvascular invasion after liver resection.
Journal: Acta chirurgica Belgica
Published: October 12, 2022
Last Updated: 09/26/2026